Trial Profile
Retrospective analysis of human Equilibrative Nucleoside Transporter 1 (hENT1) expression in pancreatic cancer in patients treated with gemcitabine or fluorouracil.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2011
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Fluorouracil
- Indications Pancreatic cancer
- Focus Biomarker; Therapeutic Use
- 24 Oct 2011 Primary endpoint 'Biomarker-levels' has been met, according to a Clavis Pharma media release.
- 24 Oct 2011 Results were reported in a Clavis Pharma media release.
- 24 Oct 2011 Status changed from recruiting to completed, according to a Clavis Pharma media release.